CTLA4 and neoplasm: Progressive insight into tumor immunology and immunosuppressive environment that favors tumor growth has paved the way for the advent of immunotherapy based on immune checkpoints (ICs) targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), which have revolutionized current therapeutic methods.